Timos Papagatsias: Interested in Social Media in the Hematology Space?
Timos Papagatsias, CEO of LucidQuest, shared on LinkedIn:
”Interested in social media in the Hematology space?
Download our ASH24 social media report!
Our team monitored and analyzed ASH-related posts on X (previously Twitter) before, during, and after the event. Here are some key takeaways:
Key Hashtags: mmsm led the discussion, emphasizing Multiple Myeloma, followed by lymsm and leusm. Hashtags like Med Twitter, mpnsm, Moffitt ASH24, MedEd, and Blood Journals also garnered significant traction, reflecting a broad and dynamic conversation around hematological research and treatment.
Top Discussion Themes: Data was the primary focus (~17.7%), highlighting the importance of evidence-based insights.
Efficacy followed closely (~16.2%), with Clinical Trials at ~13.7%. Additional themes around Treatments, patient perspectives, and Safety highlighted the drive towards more effective and patient-centered care.
Leading Voices: Doctors dominated the conversation (~56%), with Education-related and Media accounts contributing ~8% and ~10% respectively.
Research (~12%), Company (~2%), and Advocate (~10%) accounts were also active, while Nurses again scored low (~2%) in high-volume posts.
Audience Sentiment: The sentiment was overwhelmingly positive (~85%), celebrating the event’s educational value and novel insights.
About 10% were neutral, offering real-time updates and general information, while ~5% expressed negative feedback, primarily regarding session overcrowding and issues with the conference app.
Text Analytics: Discussions centered on patient-centric, data-driven approaches in Multiple Myeloma and Lymphoma management.
Treatments like CART therapy and Daratumumab attracted considerable attention, reflecting the growing impact of advanced therapeutics in hematology.
If you’re interested in social media coverage during conferences, send us a message at [email protected]; we cover multiple therapyareas and events!”
Stay updated with Hemostasis Today.
-
Nov 30, 2025, 13:23Ditte Vestergaard Hansen and Colleagues on Predictors of VTE Post-Stroke
-
Nov 30, 2025, 13:10Divyaswathi Citla Sridhar and Team Report Higher VTE Rates in Obese Users of Certain Estrogen-Progestin Combinations
-
Nov 30, 2025, 12:15Raphaël Liévin: In March 2026 SFH Will Host Its Very First Young EHA Research Meeting (YERM)!
-
Nov 30, 2025, 11:51Mohamed Aly Saad Aly on Microcatheters for Superselective Arterial Embolization
-
Nov 29, 2025, 18:55Ahmad Thuaimer: Success Story – Advanced Interventional Care for DVT
-
Nov 29, 2025, 17:37Almahdi Ali Explores Ipsilateral Paradoxical Thromboembolism at 22nd European Angiology Days 2025
-
Nov 29, 2025, 17:23Jack Shuang Hou Shares Major Neurology Updates This Week
-
Nov 29, 2025, 16:52Federica Fogacci on Further Strengthening Collaboration Within the Lp(a)CCELERATE Study
-
Nov 29, 2025, 16:42Dr Abdul Mannan on the Echinocyte: Mastering the Diagnostic Duality of Artifact vs. Pathology